Araştırma özeti
Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by
Background and aimsThis study aimed to systematically phenotype autonomic nervous system (ANS) involvement in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), monoclonal gammopathy of undetermined significance-associated neuropathy (MGUS-PNP), Charcot-Marie-Tooth disease Type 1A (CMT1A), and hereditary neuropathy with liability to pressure palsies (HNPP).MethodsAutonomic symptoms were assessed using the SCales for Outcomes in Parkinson's Disease-Autonomic Dysfunction (SCOPA-AUT). Muscle strength and functional disability were evaluated using the Medical Research Council (MRC) scale, the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale, and the Overall Neuropathy Limitation Scale (ONLS).ResultsA total of 343 participants were included: 98 with CIDP (mean age: 59.2 ± 13.2 years), 51 with MGUS-PNP (66.0 ± 11.3 years), 51 with CMT1A (51.2 ± 13.1 years), 18 with HNPP (40.6 ± 15.1 years), and 125 healthy controls (58.2 ± 13.3 years). Compared with healthy controls, patients with CIDP, MGUS-PNP, and CMT1A showed significantly higher total SCOPA-AUT scores (p InterpretationPatients with CIDP, MGUS-PNP, and CMT1A exhibit a substantial autonomic symptom burden with distinct disease-specific ANS patterns. These findings highlight the relevance of autonomic dysfunction in immune-mediated and hereditary neuropathies and warrant further studies to clarify their clinical and prognostic significance.
Bilimsel değerlendirme
Araştırma sorusu
Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.
Yöntem ve örneklem
Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.
Temel bulgular
Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.
Sınırlılıklar
Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.
Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.